These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Feb 13, 2014Agenus gains powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets
Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today...
Feb 10, 2014
Agenus Inc. (Nasdaq: AGEN) today announced the closing of its previously announced underwritten registered public offering of common stock. The total number of shares of common stock sold was...
Feb 6, 2014
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced that the company will be presenting at...
Feb 5, 2014
Agenus Inc. (Nasdaq: AGEN) today announced the pricing of an underwritten public offering of 19,335,653 primary shares of its common stock at a price of $2.70 per share. Agenus has granted the...
Jan 21, 2014Agenus’ Prophage Vaccine for Glioma Hailed As a ‘Very Promising Therapy’ in an Editorial Published in the Journal Neuro-Oncology
Agenus Inc. (Nasdaq: AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200...